Ariella Bar‐Gil Shitrit

Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti‐TNF or conventional therapy: results of the European CONCEIVE study

Annick Moens, C. Janneke van der Woude, Mette Julsgaard et al. · Alimentary Pharmacology & Therapeutics · 2019 · 138 citations · Full text

Medicine, Immunology, Obstetrics +14

Diagnostic Value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 Assays in Pleural Effusions: Analysis of 116 Cases and Review of the Literature

David Shitrit, Ariella Bar‐Gil Shitrit, Dekel Shlomi et al. · The Oncologist · 2005 · 132 citations · Full text

Medicine, Oncology, Pathology +16

Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab

Bella Ungar, Uri Kopylov, Tal Engel et al. · Alimentary Pharmacology & Therapeutics · 2016 · 116 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +17

Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease—the Israeli Real-World Experience

Uri Kopylov, Yulia Ron, Irit Avni‐Biron et al. · Inflammatory Bowel Diseases · 2017 · 100 citations

Pharmacy, Clinical Sciences, Pharmacotherapy +16

Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα

Hadar Edelman-Klapper, Eran Zittan, Ariella Bar‐Gil Shitrit et al. · Gastroenterology · 2021 · 92 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17